IOL Chemicals and Pharmaceuticals Ltd. reported a strong performance for the quarter ended June 30, 2025 (Q1 FY26), with net profit rising 13.3% year-on-year to ₹34 crore, compared to ₹30 crore in Q1 FY25.
Revenue for the quarter stood at ₹552 crore, up 10% from ₹502 crore in the corresponding period last year, driven by improved sales across its active pharmaceutical ingredients (API) and specialty chemicals divisions.
EBITDA for the quarter rose sharply by 22.5% to ₹63 crore, compared to ₹51 crore in the year-ago quarter. The company also reported an improvement in EBITDA margin to 11.4%, up from 10.2% YoY, reflecting better operating leverage and cost efficiencies.
The consistent growth in profitability and margin expansion indicates operational stability and rising demand in the company’s core business verticals.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.